The first two patients with abdominal aortic aneurysms (AAA) have been treated with Endologix’s Ovation Alto abdominal stent graft system. The patients were treated by Andrew Holden and Andrew Hill of Auckland City Hospital, Auckland, New Zealand.
The one-year results from Intact Vascular’s Tack Optimized Balloon Angioplasty (TOBA) clinical study have been published in the Journal of Vascular Surgery.
New US research indicates that there was a widespread and steady decline in elective open abdominal aortic aneurysm repairs for Medicare patients from 2003 to 2013, coinciding with a “dramatic” substitution of endovascular aneurysm repair (EVAR) across all geographic areas and a strikingly fast adoption of branched/fenestrated EVAR.
A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life scores improved significantly, and return to work and normal activity times were short. The data showed that treatment of multiple segments in one setting, large veins and superficial veins was safe, with further three-month follow-up now being analysed.
Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial (EU RCT) at the Amputation Prevention Symposium (AMP; 10–13 August, Chicago, USA). The EU RCT Trial enrolled 328 patients, 295 of whom were randomised to treatment with the Stellarex drug-coated balloon (DCB) or a percutaneous transluminal angioplasty (PTA).
Corindus Vascular Robotics has announced that J Aaron Grantham, an interventional cardiologist specialising in the treatment of chronic total occlusions, has joined the company as chief medical officer.
InSeal Medical has received CE mark approval for its InClosure VCD; a large bore vascular closure device. According to a press release, the InClosure VCD is a first-in-class, intravascular closure device based on InSeal Medical’s proprietary and patented technology.
Further sub-group analysis of CORAL trial data indicates that retrieval of renal function after renal artery stenting improves survival and decreases cardiovascular and renal events. J Gregory Modrall, University of Texas Southwestern Medical Center, Dallas, USA, who presented the analysis at the Vascular Annual Meeting (9–11 June, National Harbor, USA), suggested that renal artery stenting in conjunction with angiotensin receptor blocker therapy may be beneficial in some patients with chronic kidney disease.
At the Vascular Annual Meeting (9–11 June, National Harbor, USA), data were presented suggesting that complex triple or quadruple fenestrated endovascular aneurysm repair (FEVAR) does not result in higher mortality or morbidity rates than standard double FEVAR in the treatment of complex aortic aneurysms.
Gore has announced US Food and Drug Administration (FDA) approval of the Gore Tigris vascular stent, a dual-component stent with a unique fluoropolymer/nitinol design. The Gore Tigris device, which gained CE mark approval in 2011, is a third-generation, self-expanding stent. The device was designed explicitly to improve anatomical conformability with the natural movement of the knee when treating peripheral arterial disease.
Essential Medical has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin the US clinical trial of X-Seal, the company’s 6F vascular closure device.
Sanford Vascular Innovations, a division of Sanford Health, has receive US Food and Drug Administration approval to study the Unitary Manifold stent graft system device to treat complex aneurysms occurring in the descending aorta.
Medtronic and VIVA Physicians reported on 27 July 2016 the first patient enrolled in the REALITY Study. The VIVA-sponsored study is assessing outcomes for patients with significantly calcified and symptomatic femoropopliteal peripheral artery disease, following adjunctive use of directional atherectomy and drug-coated balloon (DCB). Krishna Rocha-Singh, chief scientific officer, Prairie Heart Institute of Illinois, and Brian DeRubertis, associate professor of surgery, UCLA Division of Vascular Surgery, are co-principal investigators. The study will include investigative sites both within the USA and in Germany.
The UK National Institute for Health and Care Excellence (NICE) has developed a Medtech Innovation Briefing (MIB) on the Lutonix drug-coated balloon (DCB) for peripheral arterial disease. Lutonix (Bard) is a paclitaxel-coated percutaneous transluminal angioplasty catheter indicated for treating peripheral arterial disease.
Frans Moll, professor of Vascular Surgery at the University Medical Center Utrecht, Utrecht, The Netherlands, has received an Honorary Fellowship of the Royal College of Surgeons of Thailand (RCST) during the College’s Annual Scientific Congress in Pattaya, Thailand (16–19 July).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos